Results 221 to 230 of about 13,011 (272)

Deferasirox (ExJade): An FDA-Approved AIEgen Platform with Unique Photophysical Properties

Journal of the American Chemical Society, 2021
Deferasirox, ExJade, is an FDA-approved iron chelator used for the treatment of iron overload. In this work, we report several fluorescent deferasirox derivatives that display unique photophysical properties, i.e., aggregation-induced emission (AIE ...
Adam Charles Sedgwick, Kai-Cheng Yan, Daniel N Mangel   +2 more
exaly   +2 more sources

Tuning the Solid- and Solution-State Fluorescence of the Iron-Chelator Deferasirox

Journal of the American Chemical Society, 2022
Deferasirox, an FDA-approved iron chelator, has gained increasing attention for use in anticancer and antimicrobial applications. Recent efforts by our group led to the identification of this core as an easy-to-visualize aggregation-induced emission ...
Xi-Le Hu, Adam Charles Sedgwick, Daniel N Mangel   +2 more
exaly   +2 more sources

Deferasirox

Drugs, 2012
exaly   +4 more sources

Oxidative Stress and Renal Function in Pediatric Patients with Beta Thalassemia Major (β-TM) Receiving Deferiprone and Deferasirox: A Cross-Sectional, Single Center Study

Research Journal of Pharmacy and Technology, 2023
Oxidative stress in β-TM (beta-thalassemia major) patients is associated with increased of malondialdehyde (MDA) level and also decreased of superoxide dismutase (SOD) level. Deferiprone and deferasirox, which are used for the treatment of iron overload,
Andreas Budi Wijaya, Wulandewi Marhaeni, T. Triawanti, Wivina Riza Devi, M. Saputra, G. Rahman   +5 more
semanticscholar   +1 more source

New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study [PDF]

American Journal of Hematology, 2017
Once-daily deferasirox dispersible tablets (DT) have a well-defined safety and efficacy profile and, compared with parenteral deferoxamine, provide greater patient adherence, satisfaction, and quality of life.
Ali T Taher, Raffaella Origa, Silverio Perrotta   +2 more
exaly   +3 more sources

Evidence for the Metabolic Activation of Deferasirox In Vitro and In Vivo.

Chemical Research in Toxicology, 2023
Deferasirox (DFS) is used for the treatment of iron accumulation caused by the need for long-term blood transfusions, such as thalassemia or other rare anemia.
Mengdie Su, Yanjia Zhao, Mei Li, Chenyang Jia, He Liu, Yue Zhang, Weiwei Li, Ying Peng, Jiang Zheng   +8 more
semanticscholar   +1 more source

Development and Validation of Rapid RP-HPLC Method for determination of Deferasirox in Bulk and Tablet Dosage Forms

Asian Journal of Pharmaceutical Analysis, 2022
The reverse phase high performance liquid chromatographic method has been developed for the estimation of Deferasirox in bulk and in tablet dosage form. Further optimized HPLC method was validated as per the current ICH guidelines.
Santhosh Kumar Ettaboina, Komalatha Nakkala, N. Chathalingath   +2 more
semanticscholar   +1 more source

Pt(IV)-Deferasirox Prodrug Combats DNA Damage Repair by Regulating RNA N6-Methyladenosine Methylation.

Journal of Medicinal Chemistry, 2022
DNA damage repair is considered to be an important mechanism of cisplatin resistance, and the roles of iron homeostasis in action mechanisms of cisplatin have not been studied yet.
Zheng‐Yin Pan, Yuyi Ling, Hang Zhang, Liang Hao, Cai-Ping Tan, Z. Mao   +5 more
semanticscholar   +1 more source